{"id":"W3128342266","doi":"10.1016/j.jtho.2021.01.1605","title":"A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Janssen Biotech; Foundation Medicine; Chugai Pharmaceutical; Genentech; Clinical Excellence Commission; Lunit; Relay Therapeutics; Northwell Health; Apollomics; Pfizer; Incyte; Siemens Medical Solutions USA; AstraZeneca; Novocure; Commission for Environmental Cooperation; MedStar Health Research Institute; Regeneron Pharmaceuticals; Array BioPharma; Agios Pharmaceuticals; Roche; Novartis; Heron Therapeutics; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Medtronic; Ariad Pharmaceuticals; Siemens Healthineers; Amgen; Boehringer Ingelheim; Exelixis; American Lung Association","keywords":"Medicine; Lung cancer; Cancer; Internal medicine; Oncology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001102325,0.001516255,0.002202503,0.0004003967,0.0004984458,0.001329254,0.0007510454,0.001683415,0.004669655],"category_scores_gemma":[0.0009238744,0.0006104393,0.002061488,0.0003349996,0.0007008113,0.001061263,0.0003020102,0.0038618,0.0009043782],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001165646,"about_ca_system_score_gemma":0.00142682,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001697853,"about_ca_topic_score_gemma":0.004793028,"domain_scores_codex":[0.9996778,0.0001188235,0.00001211265,0.00006782269,0.00002602627,0.00009743814],"domain_scores_gemma":[0.9994841,0.00009040009,0.00006533282,0.00003774256,0.00004428775,0.0002781347],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8225145,0.04133708,0.00600482,0.0009576043,0.002712722,0.0004358753,0.0002548071,0.003363695,0.03048236,0.000451353,0.008508621,0.08297657],"study_design_scores_gemma":[0.743371,0.2339651,0.01213951,0.00005428046,0.0009371532,0.0004235092,0.00009729023,0.001868891,0.002459775,0.0002504261,0.00438494,0.00004824389],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9892628,0.002946219,0.0004170925,0.001169933,0.0003231751,0.001547575,0.001684957,0.0001055522,0.002542675],"genre_scores_gemma":[0.9880525,0.001944808,0.0008828714,0.001407321,0.000222774,0.001500289,0.003039679,0.00003420693,0.002915512],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004669655,"threshold_uncertainty_score":0.0156216,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01810293350768457,"score_gpt":0.4496206825810844,"score_spread":0.4315177490733998,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}